Phase III clinical trials in platinum-sensitive patients have demonstrated its efficacy in ovarian and prostate cancers, or in combination with anti-angiogenic agents (VEGF inhibitors) in HER2-negative, BRCA1-mutant triple-negative breast cancers (TNBC), as well as in combination with Temozolomide in melanoma patients, are clear examples exhibiting adequate pharmacokinetics and clinically relevant antitumor activity. Here, ERBB2 is linked to melanoma.